Plasma cell-free DNA measured prior to renal replacement therapy initiation is not associated with incident adverse outcomes, hospitalizations or malignancies in chronic kidney disease stage 4–5 patients
Niilo Liuhto, Jenni Tuominen, Noora Manni, Markus Hakamäki, Roosa Lankinen, Tomi Toukola, Jonna Virtanen, Kaj Metsärinne · 2026
Read Plasma cell-free DNA measured prior to renal replacement therapy initiation is not associated with incident adverse outcomes, hospitalizations or malignancies in chronic kidney disease stage 4–5 patients by Niilo Liuhto, Jenni Tuominen, Noora Manni, Markus Hakamäki, Roosa Lankinen, Tomi Toukola, Jonna Virtanen, Kaj Metsärinne (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0353258.txt.
Description
Niilo Liuhto and seven colleagues report this 2026 PLOS One study testing whether fragments of DNA floating in blood predict bad outcomes in advanced kidney disease. Such cell-free DNA is a newer inflammation marker never checked in patients whose kidneys are failing but who have not yet started dialysis. The team measured it in nearly one hundred forty patients and followed them for several years.
The marker predicted nothing: not deaths, heart events, emergency visits, hospital stays, or new cancers. Levels did rise later in patients who moved on to transplants or dialysis, suggesting the treatment stage itself shifts the marker. The authors present the negative result as useful guidance, sparing future studies from chasing a marker that does not deliver in this group.
Catalog record
| CREATOR | Niilo Liuhto, Jenni Tuominen, Noora Manni, Markus Hakamäki, Roosa Lankinen, Tomi Toukola, Jonna Virtanen, Kaj Metsärinne |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37428 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |